Clinical Trial Detail

NCT ID NCT02300935
Title Study of Trametinib and Nab-paclitaxel in Patients With Melanoma
Recruitment Withdrawn
Gender both
Phase Phase I
Variant Requirements No
Sponsors SCRI Development Innovations, LLC
Indications

melanoma

Therapies

Nab-paclitaxel + Trametinib

Age Groups: adult

No variant requirements are available.